Volitionrx Ltd (VNRX) Stock Price, Quote & News

Company Profile

VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes; Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progre...

Industry: Medical Devices

Sector: Healthcare

Phone: 646 650 1351

Website: volition.com

Address:

1489 West Warm Springs Road, Suite 110, Henderson, United States

Stockprofiler May. 15 at 7:30 PM

$VNRX just reported Q1 2026 revenue of $1.0M — 5x higher than Q1 2025. Cash burn expected to drop 25–30% this year. Feline lymphoma publication could trigger a $5M milestone.

0 · Reply

EarningsInsider May. 15 at 1:45 PM

https://www.marketbeat.com/earnings/reports/2026-5-14-volitionrx-limited-stock/ $VNRX VolitionRX Earnings Transcript

0 · Reply

MulaBagz May. 15 at 1:15 PM

$VNRX

0 · Reply

St0ckman691 May. 15 at 12:22 PM

$VNRX solid Q1 financials reported yesterday! Revenues up and operating loss down: https://finance.yahoo.com/sectors/healthcare/articles/volitionrx-limited-announces-first-quarter-201000328.html

0 · Reply

PrnceMichael May. 15 at 12:04 PM

$VNRX Event: VolitionRx Limited First Quarter 2026 Earnings and Business Update Conference Call Date: Friday, May 15, 2026 Time: 8:30 a.m. U.S. Eastern Time/2.30 p.m. Central European Time U.S. & Canada Dial-in: 1-877-407-9716 (toll free) U.K. Dial-in: 0 800 756 3429 (toll free) Toll/International: 1-201-493-6779 Conference ID: 13760656

0 · Reply

StocktwitsEarnings May. 15 at 10:30 AM

$VNRX Q1 '26 Earnings Results & Recap VolitionRX Ltd reported total revenues of $985,076 for Q1 2026, a significant increase from $246,385 in Q1 2025, driven by product sales. Net loss increased to $6.7M from $5.5M year-over-year. Cash and cash equivalents reached $3.1M.

0 · Reply

MulaBagz May. 14 at 9:43 PM

$VNRX massive rev high cash burn tho… let’s see

0 · Reply

VinWeezel May. 14 at 8:34 PM

$VNRX https://www.stocktitan.net/news/VNRX/volition-rx-limited-announces-first-quarter-2026-financial-results-c73jf3ma655l.html

1 · Reply

Stockprofiler May. 14 at 7:31 PM

$VNRX VolitionRx (NYSE AMERICAN: VNRX) will host its first quarter 2026 earnings and business update conference call on Friday, May 15, 2026 at 8:30 a.m. U.S. Eastern Time (2:30 p.m. CET). Senior management will review financial and operating results, key events, and upcoming milestones, with live webcast and replay available. https://www.stocktitan.net/news/VNRX/volition-rx-limited-schedules-first-quarter-2026-earnings-conference-93r2p23xygwq.html @VolitionRx @NYSE

0 · Reply

MulaBagz May. 14 at 5:58 PM

$VNRX curled up tight

0 · Reply

VolitionRx Earnings Call Transcript: Q1 2026

2026-05-14T21:21:26.000Z - 1 day ago

VolitionRx reports Q1 revenue $1M, consensus $409,920

May 14, 2026, 4:10 PM EDT - 1 day ago

VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update

May 11, 2026, 8:19 AM EDT - 4 days ago

VolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business Update

2026-05-07T06:07:48.000Z - 8 days ago

VolitionRx submits manuscript for Nu.Q Vet cancer test in cats

May 6, 2026, 8:17 AM EDT - 9 days ago

VolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats

2026-04-29T14:40:22.000Z - 16 days ago

VolitionRx announces milestone in nucleosomes detection

Apr 29, 2026, 8:17 AM EDT - 16 days ago

Volition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis Testing

2026-04-23T12:21:08.000Z - 22 days ago

VolitionRx’s compliance plan accepted by NYSE American

Apr 23, 2026, 8:12 AM EDT - 22 days ago

VolitionRx Announces Acceptance of Compliance Plan by NYSE American

2026-04-20T12:05:06.000Z - 25 days ago

VolitionRx downgraded to Hold from Buy at D. Boral Capital

Apr 20, 2026, 7:30 AM EDT - 25 days ago

Volition Launches rNuQ™ Webshop Broadening Product Range

2026-04-02T16:11:44.000Z - 6 weeks ago

VolitionRx price target lowered to $1 from $1.50 at H.C. Wainwright

Apr 1, 2026, 8:30 AM EDT - 6 weeks ago

VolitionRx Earnings Call Transcript: Q4 2025

Mar 31, 2026, 4:05 PM EDT - 6 weeks ago

VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update

Mar 31, 2026, 8:16 AM EDT - 6 weeks ago

VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium

Mar 30, 2026, 8:13 AM EDT - 6 weeks ago

Volition Announces Mayo Clinic Study Demonstrates Nu.Q® Concentrations are Elevated in Trauma Patients

Mar 26, 2026, 8:17 AM EDT - 7 weeks ago

Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference

Mar 25, 2026, 4:12 PM EDT - 7 weeks ago

VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update

2026-03-25T13:04:07.000Z - 7 weeks ago

Why is VolitionRX Stock (VNRX) Up 24% Today?

Mar 25, 2026, 8:17 AM EDT - 7 weeks ago

Volition Announces Detection of Over 95% of Early-Stage Cancers

Mar 18, 2026, 8:17 AM EDT - 2 months ago

Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA

2026-03-06T13:18:03.000Z - 2 months ago

VolitionRx announces automated Nu.Q Vet Cancer Test with Fujifilm Vet Systems

Mar 6, 2026, 8:10 AM EST - 2 months ago

Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems

Feb 25, 2026, 8:10 AM EST - 2 months ago

VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution

Feb 10, 2026, 8:07 AM EST - 3 months ago

Volition Announces the Appointment of New Distributor for Nu.Q® Discover

2026-02-09T22:25:09.000Z - 3 months ago

VolitionRx receives non-compliance notice from NYSE American

2026-02-09T22:20:16.000Z - 3 months ago

VolitionRx files to sell 17.97M shares of common stock for holders

Feb 9, 2026, 5:20 PM EST - 3 months ago

VolitionRx Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

Feb 4, 2026, 8:45 AM EST - 3 months ago

Volition Sponsors Symposium at 15th Conference of the European Hidradenitis Suppurativa Foundation

2026-01-30T13:55:53.000Z - 3 months ago

VolitionRx preparing reimbursement submission for Nu.Q cancer assays in France

Jan 30, 2026, 8:50 AM EST - 3 months ago

VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays

Jan 27, 2026, 8:00 AM EST - 3 months ago

Volition Announces Data to Support Use of Nu.Q® NETs in New Indication

2026-01-20T13:38:55.000Z - 4 months ago

VolitionRx adds two laboratories providing its vet cancer test in U.S. and Asia

Jan 20, 2026, 8:25 AM EST - 4 months ago

Volition Continues to Extend Access to Nu.Q® Vet Cancer Test

Jan 16, 2026, 8:45 AM EST - 4 months ago

Volition Sponsors Symposium at Veterinary Meeting and Expo

Jan 8, 2026, 9:15 AM EST - 4 months ago

VolitionRx Secures $2.0 Million in Funding

2026-01-08T13:51:44.000Z - 4 months ago

VolitionRx announces clinical data for Nu.Q Vet cancer test in cats

Jan 8, 2026, 8:45 AM EST - 4 months ago

VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats

Dec 17, 2025, 8:45 AM EST - 5 months ago

Volition Issues Business Review 2025

2025-12-11T14:15:38.000Z - 5 months ago

VolitionRx announces new paper on Capture-Seq, achieves 180-fold enrichment

Dec 11, 2025, 9:00 AM EST - 5 months ago

Volition Solves Liquid Biopsy's "Needle in a Haystack" Problem; Achieves 180-fold (18,000%) Enrichment

Dec 8, 2025, 9:00 AM EST - 5 months ago

Volition Announces Two Abstracts were Presented at the North America Conference on Lung Cancer

Dec 4, 2025, 9:00 AM EST - 5 months ago

VolitionRx Limited Announces Inclusion of its Nu.Q® NETs Assay as Innovative Biomarker in France's Real-World Evaluation of Early Detection of Sepsis

2025-12-03T13:00:30.000Z - 5 months ago

VolitionRx downgraded to Hold from Buy at Maxim

Nov 25, 2025, 8:45 AM EST - 6 months ago

VolitionRx Limited Announces the First Sale of the Nu.Q® Cancer Assays for Clinical Certification in Preparation for Routine Clinical Use

2025-11-17T16:25:14.000Z - 6 months ago

VolitionRx price target lowered to $1.50 from $2.50 at H.C. Wainwright

Nov 14, 2025, 8:30 AM EST - 6 months ago

VolitionRx Earnings Call Transcript: Q3 2025

2025-11-13T21:22:31.000Z - 6 months ago

VolitionRx reports Q3 revenue $600,000, consensus $715,590

Nov 13, 2025, 4:10 PM EST - 6 months ago

VolitionRx Limited Announces Third Quarter 2025 Financial Results and Business Update

Nov 10, 2025, 8:45 AM EST - 6 months ago

VolitionRx Limited Schedules Third Quarter 2025 Earnings Conference Call and Business Update

Oct 17, 2025, 8:00 AM EDT - 7 months ago

Volition Donates Nu.Q® Vet Cancer Tests to HOPE Animal-Assisted Crisis Response Dogs

2025-10-10T12:35:51.000Z - 7 months ago

VolitionRx announces pricing of $6M offering of common stock, warrants

Oct 10, 2025, 8:30 AM EDT - 7 months ago

VolitionRx Limited Announces Pricing of $6.0 Million Underwritten Public Offering of Common Stock and Common Stock Warrants

Oct 9, 2025, 4:05 PM EDT - 7 months ago

VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock and Common Stock Warrants

Oct 8, 2025, 11:00 AM EDT - 7 months ago

VolitionRx Transcript: Status Update

Oct 2, 2025, 8:45 AM EDT - 8 months ago

Volition Sponsors Upcoming GenomeWeb Webinar

Sep 29, 2025, 9:30 AM EDT - 8 months ago

Volition Signs Co-Marketing and Services Agreement with Hologic

HOLX

Sep 9, 2025, 8:45 AM EDT - 8 months ago

Volition Signs First Human Out Licensing Deal

Aug 15, 2025, 8:30 AM EDT - 9 months ago

VolitionRx Earnings Call Transcript: Q2 2025

Aug 14, 2025, 4:10 PM EDT - 9 months ago

VolitionRx Limited Announces Second Quarter 2025 Financial Results and Business Update

Aug 8, 2025, 8:30 AM EDT - 10 months ago

VolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update

Aug 4, 2025, 4:01 PM EDT - 10 months ago

VolitionRx Announces Pricing of $1.2 Million Registered Direct Offering

Jul 16, 2025, 8:00 AM EDT - 10 months ago

Nu.Q® Discover Expands Global Adoption and Epigenetic Innovation

Jul 8, 2025, 8:00 AM EDT - 11 months ago

Volition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of Nucleosomes

Jun 12, 2025, 8:30 AM EDT - 1 year ago

Volition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure

Jun 4, 2025, 9:00 PM EDT - 1 year ago

Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties

May 19, 2025, 8:30 AM EDT - 1 year ago

VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats

May 16, 2025, 8:30 AM EDT - 1 year ago

VolitionRx Earnings Call Transcript: Q1 2025

May 15, 2025, 5:37 PM EDT - 1 year ago

VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update

May 12, 2025, 8:30 AM EDT - 1 year ago

VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update

May 7, 2025, 8:30 AM EDT - 1 year ago

VolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoption

Apr 29, 2025, 8:30 AM EDT - 1 year ago

VolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar markets

Mar 31, 2025, 4:30 PM EDT - 1 year ago

VolitionRx Earnings Call Transcript: Q4 2024

Mar 31, 2025, 4:05 PM EDT - 1 year ago

VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update

Stockprofiler May. 15 at 7:30 PM

$VNRX just reported Q1 2026 revenue of $1.0M — 5x higher than Q1 2025. Cash burn expected to drop 25–30% this year. Feline lymphoma publication could trigger a $5M milestone.

0 · Reply

EarningsInsider May. 15 at 1:45 PM

https://www.marketbeat.com/earnings/reports/2026-5-14-volitionrx-limited-stock/ $VNRX VolitionRX Earnings Transcript

0 · Reply

MulaBagz May. 15 at 1:15 PM

$VNRX

0 · Reply

St0ckman691 May. 15 at 12:22 PM

$VNRX solid Q1 financials reported yesterday! Revenues up and operating loss down: https://finance.yahoo.com/sectors/healthcare/articles/volitionrx-limited-announces-first-quarter-201000328.html

0 · Reply

PrnceMichael May. 15 at 12:04 PM

0 · Reply

StocktwitsEarnings May. 15 at 10:30 AM

0 · Reply

MulaBagz May. 14 at 9:43 PM

$VNRX massive rev high cash burn tho… let’s see

0 · Reply

VinWeezel May. 14 at 8:34 PM

$VNRX https://www.stocktitan.net/news/VNRX/volition-rx-limited-announces-first-quarter-2026-financial-results-c73jf3ma655l.html

1 · Reply

Stockprofiler May. 14 at 7:31 PM

0 · Reply

MulaBagz May. 14 at 5:58 PM

$VNRX curled up tight

0 · Reply

UltimateTrader_22 May. 14 at 5:57 PM

$VNRX VolitionRx just hit a breakthrough — finger-prick nucleosome detection now possible. Add a Mayo Clinic validation study, 40% revenue growth in 2025, and France reimbursement expected Q4 2026, and this early-stage biotech is one to watch. Real science. Real potential. 🧬 #Biotech #VNRX

0 · Reply

PrnceMichael May. 14 at 4:13 PM

1 · Reply

eWhispers May. 14 at 4:01 PM

#earnings before the open on Friday, May 15, 2026 https://www.earningswhispers.com/calendar $SURG $SPRY $CREX $VNRX $DGXX

1 · Reply

AveraveJoeTrader May. 14 at 2:00 PM

$VNRX On earnings alert here..hope it’s good enough to kick the shorts to the curb for good..🎉👏

1 · Reply

moemog May. 14 at 12:04 PM

$VNRX 🚀

0 · Reply

MulaBagz May. 14 at 3:57 AM

$VNRX we go moon tomorrow?

1 · Reply

AveraveJoeTrader May. 13 at 8:33 PM

$TDIC $WTI $VNRX My video watchlist had some winners.. $TDIC went above and beyond! Check it out! 🎉🎉🎉🎉🎉👇🏻👇🏻 https://x.com/autumnsdad1/status/2054659655360467409?s=61

0 · Reply